{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:54:32Z","timestamp":1790704472404,"version":"4.1.0"},"reference-count":119,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","translationalres.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Research"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.trsl.2020.04.006","type":"journal-article","created":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T12:25:07Z","timestamp":1589286307000},"page":"70-81","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":90,"special_numbering":"C","title":["Antiphospholipid syndrome"],"prefix":"10.1016","volume":"225","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1441-5373","authenticated-orcid":false,"given":"Michelle","family":"Petri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trsl.2020.04.006_bib0001","doi-asserted-by":"crossref","first-page":"524","DOI":"10.7326\/0003-4819-106-4-524","article-title":"The frequency of lupus anticoagulant in systemic lupus erythematosus. A study of sixty consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolipin antibody level","volume":"106","author":"Petri","year":"1987","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.trsl.2020.04.006_bib0002","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1177\/096120339700600510","article-title":"Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus\u2014a meta-analysis","volume":"6","author":"Wahl","year":"1997","journal-title":"Lupus"},{"key":"10.1016\/j.trsl.2020.04.006_bib0003","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1002\/art.34402","article-title":"Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies","volume":"64","author":"Lockshin","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.trsl.2020.04.006_bib0004","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1111\/j.1538-7836.2009.03555.x","article-title":"Update of the guidelines for lupus anticoagulant detection","volume":"7","author":"Pengo","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.trsl.2020.04.006_bib0005","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.thromres.2019.05.013","article-title":"Neutralising rivaroxaban induced interference in laboratory testing for lupus anticoagulant (LA): a comparative study using DOAC Stop and andexanet alfa","volume":"180","author":"Favaloro","year":"2019","journal-title":"Thromb Res"},{"key":"10.1016\/j.trsl.2020.04.006_bib0006","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1515\/cclm-2018-1197","article-title":"The effect of DOAC-Stop on lupus anticoagulant testing in plasma samples of venous thromboembolism patients receiving direct oral anticoagulants","volume":"57","author":"Z\u0105bczyk","year":"2019","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.trsl.2020.04.006_bib0007","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3899\/jrheum.120084","article-title":"Utility of antiphosphatidylserine\/prothrombin and IgA antiphospholipid assays in systemic lupus erythematosus","volume":"40","author":"Akhter","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.trsl.2020.04.006_bib0008","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1160\/TH04-06-0382","article-title":"Antiprothrombin antibodies detected in two different assay systems. Prevalence and clinical significance in systemic lupus erythematosus","volume":"93","author":"Bertolaccini","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.trsl.2020.04.006_bib0009","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1055\/s-0038-1646476","article-title":"Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin","volume":"66","author":"Bevers","year":"1991","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.trsl.2020.04.006_bib0010","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/hae.12669","article-title":"Lupus anticoagulant acquired hypoprothrombinemia syndrome in childhood: two distinct patterns and review of the literature","volume":"21","author":"Sarker","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.trsl.2020.04.006_bib0011","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S0002-9440(10)63479-7","article-title":"Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers","volume":"163","author":"Rand","year":"2003","journal-title":"Am J Pathol"},{"key":"10.1016\/j.trsl.2020.04.006_bib0012","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s11684-015-0426-7","article-title":"Anti-\u03b22 glycoprotein I antibodies in complex with \u03b22 glycoprotein I induce platelet activation via two receptors: apolipoprotein E receptor 2\u2032 and glycoprotein I b\u03b1","volume":"10","author":"Zhang","year":"2016","journal-title":"Front Med"},{"key":"10.1016\/j.trsl.2020.04.006_bib0013","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1160\/TH12-03-0212","article-title":"Platelet and endothelial activation in catastrophic and quiescent antiphospholipid syndrome","volume":"109","author":"Bontadi","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.trsl.2020.04.006_bib0014","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1136\/ard.56.3.194","article-title":"Thrombocytopenia in the antiphospholipid syndrome","volume":"56","author":"Cuadrado","year":"1997","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.trsl.2020.04.006_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2141.1996.390969.x","article-title":"Thrombocytopenia in the antiphospholipid syndrome","volume":"93","author":"Galli","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1016\/j.trsl.2020.04.006_bib0016","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nrrheum.2017.124","article-title":"Diagnosing antiphospholipid syndrome: \u201cextra-criteria\u201d manifestations and technical advances","volume":"13","author":"Sciascia","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.trsl.2020.04.006_bib0017","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1177\/096120339600500503","article-title":"Neurological aspects of antiphospholipid antibody syndrome","volume":"5","author":"Levine","year":"1996","journal-title":"Lupus"},{"key":"10.1016\/j.trsl.2020.04.006_bib0018","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1056\/NEJM200404083501518","article-title":"Premature coronary disease in systemic lupus","volume":"350","author":"Doria","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2020.04.006_bib0019","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.20433","article-title":"Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome","volume":"50","author":"Tektonidou","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.trsl.2020.04.006_bib0020","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1016\/j.ddmec.2011.12.002","article-title":"New insights into the molecular basis of the antiphospholipid syndrome","volume":"8","author":"Mineo","year":"2011","journal-title":"Drug Discov Today Dis Mech"},{"key":"10.1016\/j.trsl.2020.04.006_bib0021","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1172\/JCI39828","article-title":"Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via \u03b22GPI and apoER2","volume":"121","author":"Ramesh","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.trsl.2020.04.006_bib0022","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.3389\/fphys.2018.01840","article-title":"Mechanisms of endothelial dysfunction in antiphospholipid syndrome: association with clinical manifestations","volume":"9","author":"Vel\u00e1squez","year":"2018","journal-title":"Front Physiol"},{"key":"10.1016\/j.trsl.2020.04.006_bib0023","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1182\/blood-2010-10-313072","article-title":"Endothelial cell activation by antiphospholipid antibodies is modulated by Kr\u00fcppel-like transcription factors","volume":"117","author":"Allen","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2020.04.006_bib0024","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJMoa1312890","article-title":"Inhibition of the mTORC pathway in the antiphospholipid syndrome","volume":"371","author":"Canaud","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2020.04.006_bib0025","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/0961203315569336","article-title":"AKT\/mTORC pathway in antiphospholipid-related vasculopathy: a new player in the game","volume":"24","author":"Canaud","year":"2015","journal-title":"Lupus"},{"key":"10.1016\/j.trsl.2020.04.006_bib0026","first-page":"762","article-title":"Antiphospholipid arterial vasculopathy","volume":"16","author":"Alarc\u00f3n-Segovia","year":"1989","journal-title":"J Rheumatol"},{"key":"10.1016\/j.trsl.2020.04.006_bib0027","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/0046-8177(95)90218-X","article-title":"Spectrum of vascular pathology affecting patients with the antiphospholipid syndrome","volume":"26","author":"Hughson","year":"1995","journal-title":"Hum Patholol"},{"key":"10.1016\/j.trsl.2020.04.006_bib0028","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.hoc.2007.10.002","article-title":"The role of antiphospholipid syndrome in cardiovascular disease","volume":"22","author":"Long","year":"2008","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.trsl.2020.04.006_bib0029","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jaut.2018.07.002","article-title":"Gene expression profiling identifies distinct molecular signatures in thrombotic and obstetric antiphospholipid syndrome","volume":"93","author":"Ripoll","year":"2018","journal-title":"J Autoimmun"},{"key":"10.1016\/j.trsl.2020.04.006_bib0030","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1038\/s41467-019-09801-x","article-title":"Adenosine receptor agonism protects against NETosis and thrombosis in antiphospholipid syndrome","volume":"10","author":"Ali","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.trsl.2020.04.006_bib0031","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.93897","article-title":"Activated signature of antiphospholipid syndrome neutrophils reveals potential therapeutic target","volume":"2","author":"Knight","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.trsl.2020.04.006_bib0032","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/art.41057","article-title":"Increased adhesive potential of antiphospholipid syndrome neutrophils mediated by \u03b22 integrin Mac-1","volume":"72","author":"Sule","year":"2020","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"10.1016\/j.trsl.2020.04.006_bib0033","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1136\/annrheumdis-2017-212224","article-title":"Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and\/or antiphospholipid antibodies","volume":"77","author":"Kim","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.trsl.2020.04.006_bib0034","doi-asserted-by":"crossref","first-page":"16556","DOI":"10.1038\/s41598-017-16448-5","article-title":"Antiphospholipid antibodies increase the levels of mitochondrial DNA in placental extracellular vesicles: alarming for preeclampsia","volume":"7","author":"Tong","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.trsl.2020.04.006_bib0035","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.molimm.2004.07.043","article-title":"A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice","volume":"42","author":"Thurman","year":"2005","journal-title":"Mol Immunol"},{"key":"10.1016\/j.trsl.2020.04.006_bib0036","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/nm1121","article-title":"Heparin prevents antiphospholipid antibody\u2013induced fetal loss by inhibiting complement activation","volume":"10","author":"Girardi","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.trsl.2020.04.006_bib0037","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/art.21157","article-title":"Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia","volume":"52","author":"Pierangeli","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.trsl.2020.04.006_bib0038","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.trsl.2020.04.006_bib0039","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0272-6386(12)80543-9","article-title":"Renal thrombotic microangiopathy in patients with systemic lupus erythematosus and the antiphospholipid syndrome","volume":"20","author":"Hughson","year":"1992","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.trsl.2020.04.006_bib0040","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1136\/ard.2006.067314","article-title":"Assessment of the 2006 revised antiphospholipid syndrome classification criteria","volume":"66","author":"Kaul","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.trsl.2020.04.006_bib0041","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1136\/ard.48.12.1023","article-title":"Fluctuations of anticardiolipin antibody levels in patients with systemic lupus erythematosus: a prospective study","volume":"48","author":"Out","year":"1989","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.trsl.2020.04.006_bib0042","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1160\/TH04-12-0839","article-title":"Antibody profiles for the diagnosis of antiphospholipid syndrome","volume":"93","author":"Pengo","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.trsl.2020.04.006_bib0043","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2015-000107","article-title":"Assessment of the independent associations of IgG, IgM and IgA isotypes of anticardiolipin with thrombosis in SLE","volume":"3","author":"Domingues","year":"2016","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.trsl.2020.04.006_bib0044","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156407","article-title":"Measuring IgA anti-\u03b22-glycoprotein I and IgG\/IgA anti-domain I antibodies adds value to current serological assays for the antiphospholipid syndrome","volume":"11","author":"Pericleous","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2020.04.006_bib0045","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.cca.2016.06.025","article-title":"Clinical significance and correlations between anti-\u03b22 glycoprotein I IgA assays in antiphospholipid syndrome and\/or systemic lupus erythematosus","volume":"460","author":"Tebo","year":"2016","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.trsl.2020.04.006_bib0046","doi-asserted-by":"crossref","first-page":"e12280","DOI":"10.1371\/journal.pone.0012280","article-title":"IgA anti-beta2-glycoprotein I autoantibodies are associated with an increased risk of thromboembolic events in patients with systemic lupus erythematosus","volume":"5","author":"Sweiss","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2020.04.006_bib0047","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1006\/jaut.2000.0409","article-title":"Epidemiology of the antiphospholipid antibody syndrome","volume":"15","author":"Petri","year":"2000","journal-title":"J Autoimmun"},{"key":"10.1016\/j.trsl.2020.04.006_bib0048","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1161\/01.STR.32.8.1701","article-title":"beta(2)-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the honolulu heart program","volume":"32","author":"Brey","year":"2001","journal-title":"Stroke"},{"key":"10.1016\/j.trsl.2020.04.006_bib0049","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.autrev.2007.10.001","article-title":"Antiphospholipid antibodies, antiphospholipid syndrome and infections","volume":"7","author":"S\u00e8ne","year":"2008","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.trsl.2020.04.006_bib0050","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/00001721-200412000-00005","article-title":"Analysis of some clinical and laboratory aspects of adolescent patients with thrombosis","volume":"15","author":"Gurgey","year":"2004","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.trsl.2020.04.006_bib0051","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00277-005-1004-x","article-title":"Evaluation of thrombotic children with malignancy","volume":"84","author":"Unal","year":"2005","journal-title":"Ann Hematol"},{"key":"10.1016\/j.trsl.2020.04.006_bib0052","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1177\/0961203309360541","article-title":"Update on anti-phospholipid antibodies in SLE: the Hopkins\u2019 Lupus cohort","volume":"19","author":"Petri","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.trsl.2020.04.006_bib0053","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3899\/jrheum.111061","article-title":"Differences between male and female systemic lupus erythematosus in a multiethnic population","volume":"39","author":"Tan","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.trsl.2020.04.006_bib0054","first-page":"2531","article-title":"Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus","volume":"29","author":"Somers","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.trsl.2020.04.006_bib0055","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1002\/acr.22066","article-title":"Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature","volume":"65","author":"Andreoli","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.trsl.2020.04.006_bib0056","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1002\/art.40901","article-title":"The epidemiology of antiphospholipid syndrome: a population\u2010based study","volume":"71","author":"Duarte\u2010Garc\u00eda","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.trsl.2020.04.006_bib0057","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1212\/WNL.40.8.1190","article-title":"Antiphospholipid antibodies and cerebral ischemia in young people","volume":"40","author":"Brey","year":"1990","journal-title":"Neurology"},{"key":"10.1016\/j.trsl.2020.04.006_bib0058","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1161\/01.STR.23.2.189","article-title":"Lupus anticoagulant and anticardiolipin antibodies in young adults with cerebral ischemia","volume":"23","author":"Nencini","year":"1992","journal-title":"Stroke"},{"key":"10.1016\/j.trsl.2020.04.006_bib0059","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1161\/01.STR.28.9.1702","article-title":"Epidemiology and etiology of ischemic stroke in young adults aged 18 to 44 years in northern Sweden","volume":"28","author":"Kristensen","year":"1997","journal-title":"Stroke"},{"key":"10.1016\/j.trsl.2020.04.006_bib0060","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1177\/096120339500400413","article-title":"The presence of antiphospholipid antibodies in acute myocardial infarction","volume":"4","author":"Adler","year":"1995","journal-title":"Lupus"},{"key":"10.1016\/j.trsl.2020.04.006_bib0061","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1161\/ATVBAHA.108.182204","article-title":"Venous thrombosis in the antiphospholipid syndrome","volume":"29","author":"Farmer-Boatwright","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.trsl.2020.04.006_bib0062","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.2174\/092986710793176302","article-title":"Genetic factors as a cause of miscarriage","volume":"17","author":"Suzumori","year":"2010","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.trsl.2020.04.006_bib0063","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1093\/humrep\/14.11.2868","article-title":"A longitudinal study of pregnancy outcome following idiopathic recurrent miscarriage","volume":"14","author":"Brigham","year":"1999","journal-title":"Hum Reprod"},{"key":"10.1016\/j.trsl.2020.04.006_bib0064","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0140-6736(15)00837-5","article-title":"Stillbirths: rates, risk factors, and acceleration towards 2030","volume":"387","author":"Lawn","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.trsl.2020.04.006_bib0065","doi-asserted-by":"crossref","first-page":"e15733","DOI":"10.1097\/MD.0000000000015733","article-title":"Pregnancy outcomes in patients with primary antiphospholipid syndrome: a systematic review and meta-analysis","volume":"98","author":"Liu","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.trsl.2020.04.006_bib0066","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-000924","article-title":"Management of thrombotic and obstetric antiphospholipid syndrome: a systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"5","author":"Tektonidou","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.trsl.2020.04.006_bib0067","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1053\/j.ackd.2019.08.013","article-title":"Pregnancy in women with systemic lupus and lupus nephritis","volume":"26","author":"Maynard","year":"2019","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.trsl.2020.04.006_bib0068","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/00005792-199805000-00005","article-title":"Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients","volume":"77","author":"Asherson","year":"1998","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.trsl.2020.04.006_bib0069","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.autrev.2016.09.010","article-title":"Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of 500 patients from the International CAPS Registry","volume":"15","author":"Rodr\u00edguez-Pint\u00f3","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.trsl.2020.04.006_bib0070","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.imbio.2005.10.002","article-title":"Multiorgan failure and antiphospholipid antibodies: the catastrophic antiphospholipid (Asherson's) syndrome","volume":"210","author":"Asherson","year":"2005","journal-title":"Immunobiology"},{"key":"10.1016\/j.trsl.2020.04.006_bib0071","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1191\/0961203303lu394oa","article-title":"Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines","volume":"12","author":"Asherson","year":"2003","journal-title":"Lupus"},{"key":"10.1016\/j.trsl.2020.04.006_bib0072","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s12016-008-8107-9","article-title":"Catastrophic antiphospholipid syndrome: treatment, prognosis, and the risk of relapse","volume":"36","author":"Bucciarelli","year":"2009","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.trsl.2020.04.006_bib0073","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/rheumatology\/kes388","article-title":"GAPSS: the global anti-phospholipid syndrome score","volume":"52","author":"Sciascia","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.trsl.2020.04.006_bib0074","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood.V80.4.975.975","article-title":"Relationship of antiphospholipid antibodies to pregnancy loss in patients with systemic lupus erythematosus: a cross-sectional study","volume":"80","author":"Ginsberg","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2020.04.006_bib0075","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1055\/s-0038-1646452","article-title":"The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: a cross-sectional study","volume":"66","author":"Long","year":"1991","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.trsl.2020.04.006_bib0076","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/art.33340","article-title":"Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events","volume":"64","author":"Otomo","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.trsl.2020.04.006_bib0077","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.thromres.2018.07.011","article-title":"Diagnostics and treatment of thrombotic antiphospholipid syndrome (APS): a personal perspective","volume":"169","author":"Pengo","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.trsl.2020.04.006_bib0078","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ijlh.12507","article-title":"Laboratory testing for antiphospholipid syndrome","volume":"38","author":"Pengo","year":"2016","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.trsl.2020.04.006_bib0079","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1111\/jth.12264","article-title":"Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile","volume":"11","author":"Pengo","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.trsl.2020.04.006_bib0080","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2015-000131","article-title":"Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results","volume":"3","author":"Yelnik","year":"2016","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.trsl.2020.04.006_bib0081","doi-asserted-by":"crossref","first-page":"524","DOI":"10.7326\/0003-4819-106-4-524","article-title":"The frequency of lupus anticoagulant in systemic lupus erythematosus","volume":"106","author":"Petri","year":"1987","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.trsl.2020.04.006_bib0082","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/bjh.15062","article-title":"Haemostasis and innate immunity\u2014a complementary relationship","volume":"180","author":"Keragala","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.trsl.2020.04.006_bib0083","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3389\/fimmu.2019.00449","article-title":"Complement in the pathophysiology of the antiphospholipid syndrome","volume":"10","author":"Chaturvedi","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.trsl.2020.04.006_bib0084","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s12975-013-0295-9","article-title":"Relation of platelet C4d with all-cause mortality and ischemic stroke in patients with systemic lupus erythematosus","volume":"5","author":"Kao","year":"2014","journal-title":"Transl Stroke Res"},{"key":"10.1016\/j.trsl.2020.04.006_bib0085","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1161\/STROKEAHA.108.514687","article-title":"Platelet C4d is associated with acute ischemic stroke and stroke severity","volume":"39","author":"Mehta","year":"2008","journal-title":"Stroke"},{"key":"10.1016\/j.trsl.2020.04.006_bib0086","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2019-000318","article-title":"Platelet-bound C4d, low C3 and lupus anticoagulant associate with thrombosis in SLE","volume":"6","author":"Petri","year":"2019","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.trsl.2020.04.006_bib0087","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1182\/blood.2019003863","article-title":"Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS","volume":"135","author":"Chaturvedi","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2020.04.006_bib0088","doi-asserted-by":"crossref","first-page":"997","DOI":"10.7326\/0003-4819-117-12-997","article-title":"Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis","volume":"117","author":"Ginsburg","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.trsl.2020.04.006_bib0089","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1002\/art.22663","article-title":"Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody\u2013positive individuals","volume":"56","author":"Erkan","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.trsl.2020.04.006_bib0090","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.autrev.2014.10.019","article-title":"Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies","volume":"14","author":"Arnaud","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.trsl.2020.04.006_bib0091","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11926-010-0141-y","article-title":"Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody\u2013positive patients","volume":"13","author":"Petri","year":"2011","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.trsl.2020.04.006_bib0092","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1177\/096120339600500524","article-title":"In vivo models of thrombosis for the antiphospholipid syndrome","volume":"5","author":"Pierangeli","year":"1996","journal-title":"Lupus"},{"key":"10.1016\/j.trsl.2020.04.006_bib0093","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","article-title":"Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision)","volume":"123","author":"Marmor","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.trsl.2020.04.006_bib0094","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s12026-016-8812-z","article-title":"Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome","volume":"65","author":"Nuri","year":"2017","journal-title":"Immunol Res"},{"key":"10.1016\/j.trsl.2020.04.006_bib0095","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3899\/jrheum.161351","article-title":"Longterm hydroxychloroquine therapy and low-dose aspirin may have an additive effectiveness in the primary prevention of cardiovascular events in patients with systemic lupus erythematosus","volume":"44","author":"Fasano","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.trsl.2020.04.006_bib0096","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1136\/ard.2010.134817","article-title":"Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression","volume":"70","author":"Agmon-Levin","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.trsl.2020.04.006_bib0097","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1365-2141.2006.06322.x","article-title":"High dose calcitriol may reduce thrombosis in cancer patients","volume":"135","author":"Beer","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.trsl.2020.04.006_bib0098","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1002\/acr.22291","article-title":"25-Hydroxyvitamin D and cardiovascular disease in patients with systemic lupus erythematosus: data from a large international inception cohort","volume":"66","author":"Lertratanakul","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.trsl.2020.04.006_bib0099","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1136\/annrheumdis-2013-203622","article-title":"A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients","volume":"73","author":"Erkan","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.trsl.2020.04.006_bib0100","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa0900241","article-title":"A randomized trial of rosuvastatin in the prevention of venous thromboembolism","volume":"360","author":"Glynn","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2020.04.006_bib0101","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJM199504133321504","article-title":"The management of thrombosis in the antiphospholipid-antibody syndrome","volume":"332","author":"Khamashta","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2020.04.006_bib0102","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S0002-9343(96)00060-5","article-title":"Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry","volume":"100","author":"Finazzi","year":"1996","journal-title":"Am J Med"},{"key":"10.1016\/j.trsl.2020.04.006_bib0103","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1056\/NEJMoa035241","article-title":"A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome","volume":"349","author":"Crowther","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2020.04.006_bib0104","article-title":"Effect of antithrombotic drugs on bone health","author":"Dadwal","year":"2019","journal-title":"Z Gerontol Geriatr"},{"key":"10.1016\/j.trsl.2020.04.006_bib0105","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2020.04.006_bib0106","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/1076029615615960","article-title":"Apixaban for the secondary prevention of thrombosis among patients with antiphospholipid syndrome","volume":"22","author":"Woller","year":"2016","journal-title":"Clin Appl Thromb"},{"key":"10.1016\/j.trsl.2020.04.006_bib0107","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1177\/0961203317699285","article-title":"Cessation of oral anticoagulants in antiphospholipid syndrome","volume":"26","author":"Comarmond","year":"2017","journal-title":"Lupus"},{"key":"10.1016\/j.trsl.2020.04.006_bib0108","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/0961203317721751","article-title":"Anticoagulation withdrawal in antiphospholipid syndrome: a retrospective matched-control study","volume":"27","author":"Yelnik","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.trsl.2020.04.006_bib0109","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/art.37759","article-title":"A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome","volume":"65","author":"Erkan","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.trsl.2020.04.006_bib0110","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1016\/j.semarthrit.2015.07.008","article-title":"Two cases of thrombosis in patients with antiphospholipid antibodies during treatment of immune thrombocytopenia with romiplostim, a thrombopoietin receptor agonist","volume":"45","author":"LaMoreaux","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.trsl.2020.04.006_bib0111","first-page":"169","article-title":"Catastrophic antiphospholipid syndrome associated with systemic lupus erythematosus treated with rituximab: case report and a review of the literature","volume":"40","author":"Sukara","year":"2015","journal-title":"Acta Rheumatol Port"},{"key":"10.1016\/j.trsl.2020.04.006_bib0112","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.autrev.2013.05.004","article-title":"Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab","volume":"12","author":"Berman","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.trsl.2020.04.006_bib0113","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10238-019-00565-8","article-title":"Eculizumab in refractory catastrophic antiphospholipid syndrome: a case report and systematic review of the literature","volume":"19","author":"Tinti","year":"2019","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.trsl.2020.04.006_bib0114","doi-asserted-by":"crossref","first-page":"e12584","DOI":"10.1097\/MD.0000000000012584","article-title":"Eculizumab in a pregnant patient with laboratory onset of catastrophic antiphospholipid syndrome","volume":"97","author":"Rovere-Querini","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.trsl.2020.04.006_bib0115","doi-asserted-by":"crossref","first-page":"254","DOI":"10.23736\/S0031-0808.17.03324-9","article-title":"Catastrophic antiphospholipid syndrome: an update","volume":"59","author":"Espinosa","year":"2017","journal-title":"Panminerva Med"},{"key":"10.1016\/j.trsl.2020.04.006_bib0116","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1001\/jama.1991.03470020086038","article-title":"A meta-analysis of low-dose aspirin for the prevention of pregnancy-induced hypertensive disease","volume":"266","author":"Imperiale","year":"1991","journal-title":"JAMA"},{"key":"10.1016\/j.trsl.2020.04.006_bib0117","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/0002-9378(92)91596-3","article-title":"Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment","volume":"166","author":"Cowchock","year":"1992","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.trsl.2020.04.006_bib0118","doi-asserted-by":"crossref","first-page":"e13219","DOI":"10.1111\/aji.13219","article-title":"Comparison of therapeutic interventions for recurrent pregnancy loss in association with antiphospholipid syndrome: a systematic review and network meta\u2010analysis","author":"Liu","year":"2020","journal-title":"Am J Reprod Immunol"},{"key":"10.1016\/j.trsl.2020.04.006_bib0119","article-title":"Antiplatelet agents for preventing pre-eclampsia and its complications","volume":"2019","author":"Duley","year":"2019","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524420300694?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524420300694?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T12:41:23Z","timestamp":1761828083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931524420300694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":119,"alternative-id":["S1931524420300694"],"URL":"https:\/\/doi.org\/10.1016\/j.trsl.2020.04.006","relation":{},"ISSN":["1931-5244"],"issn-type":[{"value":"1931-5244","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiphospholipid syndrome","name":"articletitle","label":"Article Title"},{"value":"Translational Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trsl.2020.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}